DE60222137D1 - Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen - Google Patents

Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen

Info

Publication number
DE60222137D1
DE60222137D1 DE60222137T DE60222137T DE60222137D1 DE 60222137 D1 DE60222137 D1 DE 60222137D1 DE 60222137 T DE60222137 T DE 60222137T DE 60222137 T DE60222137 T DE 60222137T DE 60222137 D1 DE60222137 D1 DE 60222137D1
Authority
DE
Germany
Prior art keywords
dihydroisomorphine
dihydromorphine
hydromorphone
pain
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60222137T
Other languages
English (en)
Other versions
DE60222137T2 (de
Inventor
Feng Gao
Jahanara Miotto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Application granted granted Critical
Publication of DE60222137D1 publication Critical patent/DE60222137D1/de
Publication of DE60222137T2 publication Critical patent/DE60222137T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/033—Uronic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE60222137T 2001-07-27 2002-07-24 Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen Expired - Lifetime DE60222137T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30784501P 2001-07-27 2001-07-27
US307845P 2001-07-27
PCT/US2002/023553 WO2003011881A2 (en) 2001-07-27 2002-07-24 Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain

Publications (2)

Publication Number Publication Date
DE60222137D1 true DE60222137D1 (de) 2007-10-11
DE60222137T2 DE60222137T2 (de) 2008-06-05

Family

ID=23191416

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60222137T Expired - Lifetime DE60222137T2 (de) 2001-07-27 2002-07-24 Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen

Country Status (14)

Country Link
US (1) US6740641B2 (de)
EP (1) EP1412368B1 (de)
JP (1) JP4679055B2 (de)
AT (1) ATE371665T1 (de)
AU (1) AU2002329634B2 (de)
CA (1) CA2455774C (de)
CY (1) CY1107813T1 (de)
DE (1) DE60222137T2 (de)
DK (1) DK1412368T3 (de)
ES (1) ES2292806T3 (de)
IL (2) IL160085A0 (de)
MX (1) MXPA04000825A (de)
PT (1) PT1412368E (de)
WO (1) WO2003011881A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7060708B2 (en) * 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
CA2477004C (en) * 2002-02-22 2011-05-10 Thomas Piccariello Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
EP1481078A4 (de) * 2002-02-22 2006-08-16 New River Pharmaceuticals Inc Verwendung einer peptid-arzneistoff-konjugation zur reduzierung der variabilität von arzneistoff-serumspiegeln zwischen patienten
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
GB0218811D0 (en) * 2002-08-14 2002-09-18 Cenes Ltd Salts of morphine-6-glucuronide
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
AU2004251647B2 (en) * 2003-05-29 2010-01-14 Takeda Pharmaceutical Company Limited Abuse resistant amphetamine compounds
BRPI0414876A (pt) * 2003-09-30 2006-11-21 New River Pharmaceuticals Inc compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
JP5176188B2 (ja) * 2006-04-21 2013-04-03 ディーエスエム アイピー アセッツ ビー．ブイ． オピオイド受容体拮抗薬の使用
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
FR2939436B1 (fr) * 2008-12-10 2010-12-17 Sanofi Aventis Synthese de morphine-6-glucuronide ou de l'un de ses derives
US8716350B2 (en) * 2010-03-30 2014-05-06 Algynomics Inc. Compositions and methods for the treatment of somatosensory disorders
EP2552433A4 (de) 2010-03-30 2013-11-06 Algynomics Inc Zusammensetzungen und verfahren zur behandlung somatosensorischer erkrankungen
HUE027195T2 (en) 2010-09-21 2016-10-28 Purdue Pharma Lp Buprenorphine analogues as opioid receptor agonists and / or antagonists
RU2573388C2 (ru) 2011-10-26 2016-01-20 Кемфарм Инк. Бензойная кислота, производные бензойной кислоты и конъюгаты гетероарилкарбоновой кислоты с гидроморфоном, пролекарства, способы получения и их применение
WO2014072809A2 (en) 2012-11-09 2014-05-15 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
AR094641A1 (es) 2012-12-07 2015-08-19 Purdue Pharma Lp Análogos de buprenorfina
CA2894963A1 (en) 2012-12-14 2014-06-19 Purdue Pharma L.P. Pyridonemorphinan analogs and biological activity on opioid receptors
ES2621305T3 (es) 2012-12-14 2017-07-03 Purdue Pharma Lp Morfinanos espirocíclicos y su uso
US9056836B2 (en) 2013-01-31 2015-06-16 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
CA2934913A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Ring-contracted morphinans and the use thereof
WO2015097548A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 7-beta-alkyl analogs of orvinols
US9340542B2 (en) 2013-12-26 2016-05-17 Purdue Pharma L.P. Propellane-based compounds and the use thereof
WO2015097547A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 10-substituted morphinan hydantoins
EP3087079B1 (de) 2013-12-26 2019-04-03 Purdue Pharma LP Opioidrezeptormodulierende oxabicyclo[2.2.2]oktanmorphinane
US10550088B2 (en) 2013-12-27 2020-02-04 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
US10030021B2 (en) 2014-05-27 2018-07-24 Purdue Pharma L.P. Spirocyclic morphinans and use thereof
CA2951697A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Azamophinan derivatives and use thereof
RU2683274C2 (ru) 2014-12-02 2019-03-27 Кемфарм, Инк. Бензойная кислота, производные бензойной кислоты и конъюгаты гетероарилкарбоновой кислоты и оксиморфона, их пролекарства, способы получения и применение
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
ITUB20154996A1 (it) 2015-10-27 2017-04-27 Nobili S P A Attrezzatura per l?erogazione di un liquido di trattamento ad una rispettiva coltura o piantagione agricola.
JP2019522032A (ja) 2016-07-29 2019-08-08 ヤンセン ファーマシューティカ エヌ．ベー． 前立腺癌の治療方法
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
WO2020012248A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Novel naphthylenyl compounds for long-acting injectable compositions and related methods
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
WO2024042226A2 (en) * 2022-08-25 2024-02-29 Biosynth Gmbh Procedure for production of opioid-antagonist-releasing compounds and their use as a medicine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2058243T3 (es) 1988-01-12 1994-11-01 Baker Norton Pharma Derivados del acido glucuronico de antagonistas de opiaceos.
FR2680786B1 (fr) * 1991-09-04 1995-03-10 Irepa Procede de synthese de glucuronides d'epoxy-4,5 morphinanes.
JPH10513485A (ja) * 1995-11-29 1998-12-22 ロラボ エセ エレ オピエート性物質の糖結合体
GB9711118D0 (en) 1997-05-29 1997-07-23 Rolabo Sl Compound

Also Published As

Publication number Publication date
AU2002329634B2 (en) 2009-01-29
DE60222137T2 (de) 2008-06-05
EP1412368B1 (de) 2007-08-29
ES2292806T3 (es) 2008-03-16
WO2003011881A2 (en) 2003-02-13
CA2455774A1 (en) 2003-02-13
IL160085A (en) 2010-12-30
PT1412368E (pt) 2007-11-06
JP4679055B2 (ja) 2011-04-27
DK1412368T3 (da) 2008-01-02
CY1107813T1 (el) 2013-06-19
WO2003011881A3 (en) 2003-10-30
US20030050257A1 (en) 2003-03-13
MXPA04000825A (es) 2004-05-17
US6740641B2 (en) 2004-05-25
IL160085A0 (en) 2004-06-20
ATE371665T1 (de) 2007-09-15
CA2455774C (en) 2011-06-07
JP2005500357A (ja) 2005-01-06
EP1412368A2 (de) 2004-04-28

Similar Documents

Publication Publication Date Title
DE60222137D1 (de) Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
ES2177084T3 (es) Uso de derivados de benzohidrilo sulfinilo para tratar la somnolencia de origen medicamentoso.
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
DE50102490D1 (de) Verwendung von substituierten imidazo [1,2-a]pyridin-, -pyrimidin- und -pyrazin-3-yl-amin-derivaten zur herstellung von medikamenten zur nos-inhibierung
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
BRPI0412426A (pt) uso da zd6474 ou de um sal farmaceuticamente aceitável da mesma e de um agente antitumoral de platina, composição farmacêutica, kit, e método para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
NO20063277L (no) Farmasoytisk sammensetning av vinflunin som er ment for parenteral administrering, fremstillingsmate og anvendelse derav
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
AU1794601A (en) Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
GB0020504D0 (en) Therapeutic method
TR200102512T2 (tr) Tüm ruhsal bozukluklar, adaptasyon bozuklukları ve çeşitli kaygı-depresyon bozukluklarının tedavisinde ya da önlenmesinde yararlı tıbbi ürünlerin hazırlanması için saredutan ve onun farmasötik olarak kabul edilebilir tuzlarının kullanımı.
WO2005062992A3 (en) Substituted melatonin derivatives, process for their preparation, and methods of use
NO20031410D0 (no) Antitumorterapi innbefattende distamycinderivater
BRPI0412924A (pt) tratamento pré-operatório de dor pós-operatória
HK1044467A1 (en) Use of polycyclic thiazole systems for producing medicaments for preventing or treating obesity
ATE228843T1 (de) Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit
ATE545423T1 (de) Mittel zur behandlung von lungenkrebs
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE60216292D1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
PT1231908E (pt) Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia
NO20021337D0 (no) 4-benzylaminoquinolinkonjugater med gallesyre og deres heteroanaloger, fremgangsmåte for deres fremstilling, legemidlersom inneholder disse forbindelser og deres anvendelse
WO2004073627A3 (en) Novel therapeutic method and compositions for topical administration
TW200501958A (en) A therapeutic agent for treating a behavioral disorder

Legal Events

Date Code Title Description
8364 No opposition during term of opposition